Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
Sankaranarayanan, R., Basu, P., Kaur, P., Bhaskar, R., Singh, G. B., Denzongpa, P., Grover, R. K., Sebastian, P., Saikia, T., Oswal, K., Kanodia, R., Dsouza, A., Mehrotra, R., Rath, G. K., Jaggi, V., Kashyap, S., Kataria, I., Hariprasad, R., Sasieni, P., ... Purushotham, A. (2019). Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. Lancet Oncology, 20(11), e637-e644. https://doi.org/10.1016/S1470-2045(19)30531-5
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
Article
The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article
Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article
SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia
OCCASIONAL PAPER